Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 4/2016

01-04-2016

Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L

Auteurs: Padraig Dixon, Helen Dakin, Sarah Wordsworth

Gepubliceerd in: Quality of Life Research | Uitgave 4/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The macular degeneration quality of life (MacDQoL) instrument is a validated condition-specific measure of quality of life in patients with macular degeneration. This paper presents the first mapping algorithm to predict EQ-5D from responses to the MacDQoL instrument.

Methods

Responses to the MacDQoL and EQ-5D-3L instruments from 482 patients were collected from the IVAN multicentre trial of two alternative drug treatments for neovascular age-related macular degeneration. Regression specifications were estimated using OLS, censored least absolute deviation, Tobit and two-part models. Their predictive performance was assessed using mean squared error. An internal validation sample based on a random selection of 25 % of patients was used to assess the performance of the model estimated on the remaining 75 % of patients.

Results

A two-part model had the best predictive performance on the full sample. The covariates of this model include responses and weighted impact scores for all 23 condition-specific domains of the MacDQoL, and responses to a general MacDQoL quality of life question. The selected models were successful at predicting means and standard deviations of target populations, but prediction is weaker at the upper and lower extremes of the EQ-5D-3L distribution.

Conclusion

The mapping algorithms provide a means of predicting EQ-5D-3L index scores from MacDQoL scores, and could facilitate cost-effectiveness analyses when the latter but not the former are available to researchers. Further validation of the performance of the algorithms using external data would provide a means of establishing the robustness of the algorithms.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Voetnoten
1
Impact response categories are answered in response to questions such as ‘If I did not have macular degeneration, friendships and social life would be…’. Typical categories are ‘very much better' [scoring −3], ‘much better' [scoring −2], ‘a little better' [scoring −1], ‘the same' [scoring 0], and ‘worse’ [scoring +1].
 
2
Importance response categories are answered in response to questions such as ‘My friendships and social life are…’ with response categories ‘very important' [scoring 3], ‘important' [scoring 2], ‘somewhat important' [scoring 1], ‘not at all important’ [scoring 0].
 
Literatuur
1.
go back to reference Longworth, L., & Rowen, D. (2013). Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health, 16(1), 202–210. CrossRefPubMed Longworth, L., & Rowen, D. (2013). Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health, 16(1), 202–210. CrossRefPubMed
2.
go back to reference Tosh, J., Brazier, J., Evans, P., & Longworth, L. (2012). A review of generic preference-based measures of health-related quality of life in visual disorders. Value in Health, 15(100883818), 118–127. CrossRefPubMedPubMedCentral Tosh, J., Brazier, J., Evans, P., & Longworth, L. (2012). A review of generic preference-based measures of health-related quality of life in visual disorders. Value in Health, 15(100883818), 118–127. CrossRefPubMedPubMedCentral
3.
go back to reference Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health and Quality of Life Outcomes, 11, 6. CrossRef Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health and Quality of Life Outcomes, 11, 6. CrossRef
4.
go back to reference Brazier, J., & Dixon, S. (1995). The use of condition specific outcome measures in economic appraisal. Health Economics, 4(4), 255–264. CrossRefPubMed Brazier, J., & Dixon, S. (1995). The use of condition specific outcome measures in economic appraisal. Health Economics, 4(4), 255–264. CrossRefPubMed
5.
go back to reference Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernández Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1. CrossRefPubMedPubMedCentral Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernández Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1. CrossRefPubMedPubMedCentral
6.
go back to reference Usha, C., Jennifer, E., & Philip, J. R. (2010). Age related macular degeneration. BMJ, 340, c981. CrossRef Usha, C., Jennifer, E., & Philip, J. R. (2010). Age related macular degeneration. BMJ, 340, c981. CrossRef
7.
go back to reference Woo, J. H., Sanjay, S., & Au Eong, K.-G. (2009). The epidemiology of age-related macular degeneration in the Indian subcontinent. Acta Ophthalmologica, 87(3), 262–269. CrossRefPubMed Woo, J. H., Sanjay, S., & Au Eong, K.-G. (2009). The epidemiology of age-related macular degeneration in the Indian subcontinent. Acta Ophthalmologica, 87(3), 262–269. CrossRefPubMed
8.
go back to reference Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012). The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology, 96(5), 752–756. CrossRef Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012). The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology, 96(5), 752–756. CrossRef
9.
go back to reference Mitchell, J., & Bradley, C. (2004). Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Quality of Life Research, 13(6), 1163–1175. CrossRefPubMed Mitchell, J., & Bradley, C. (2004). Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Quality of Life Research, 13(6), 1163–1175. CrossRefPubMed
10.
go back to reference Mitchell, J., Wolffsohn, J., Woodcock, A., Anderson, S., McMillan, C., Rubinstein, M., et al. (2005). + Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health and Quality of Life Outcomes, 3(1), 25. CrossRefPubMedPubMedCentral Mitchell, J., Wolffsohn, J., Woodcock, A., Anderson, S., McMillan, C., Rubinstein, M., et al. (2005). + Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health and Quality of Life Outcomes, 3(1), 25. CrossRefPubMedPubMedCentral
11.
go back to reference Mitchell, J., Wolffsohn, J., Woodcock, A., Anderson, S. J., Ffytche, T., Rubinstein, M., et al. (2008). The MacDQoL individualized measure of the impact of macular degeneration on quality of life: Reliability and responsiveness. American Journal of Ophthalmology, 146(3), 447.e442–454.e442. CrossRef Mitchell, J., Wolffsohn, J., Woodcock, A., Anderson, S. J., Ffytche, T., Rubinstein, M., et al. (2008). The MacDQoL individualized measure of the impact of macular degeneration on quality of life: Reliability and responsiveness. American Journal of Ophthalmology, 146(3), 447.e442–454.e442. CrossRef
12.
go back to reference Berdeaux, G., Mesbah, M., & Bradley, C. (2011). Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations. Value in Health, 1(1524-4733 (Electronic)), 10. Berdeaux, G., Mesbah, M., & Bradley, C. (2011). Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations. Value in Health, 1(1524-4733 (Electronic)), 10.
13.
go back to reference Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012). Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology, 119(7), 1399–1411. CrossRefPubMed Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012). Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology, 119(7), 1399–1411. CrossRefPubMed
14.
go back to reference Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013). Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, 382, 1258. CrossRef Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013). Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, 382, 1258. CrossRef
15.
go back to reference van Reenen, M., & Oppe, M. (2015). EQ-5D-3L user guide: Basic information on how to use the EQ-5D-3L instrument version 5.1. Rotterdam: EuroQol Research Foundation. van Reenen, M., & Oppe, M. (2015). EQ-5D-3L user guide: Basic information on how to use the EQ-5D-3L instrument version 5.1. Rotterdam: EuroQol Research Foundation.
16.
go back to reference NICE. (2013). Guide to the methods of technology appraisal. Manchester: The National Institute for Health and Care Excellence. NICE. (2013). Guide to the methods of technology appraisal. Manchester: The National Institute for Health and Care Excellence.
17.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 12. CrossRef Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 12. CrossRef
18.
go back to reference Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., & Gray, A. (2015). Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Quality of Life Research, 30, 1–7. Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., & Gray, A. (2015). Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Quality of Life Research, 30, 1–7.
19.
go back to reference Wooldridge, J. M. (2009). Introductory econometrics: A modern approach. Mason: South Western, Cengage Learning. Wooldridge, J. M. (2009). Introductory econometrics: A modern approach. Mason: South Western, Cengage Learning.
20.
go back to reference Pullenayegum, E. M., Tarride, J.-E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are Tobit and CLAD models appropriate? Value in Health, 13(4), 487–494. CrossRefPubMed Pullenayegum, E. M., Tarride, J.-E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are Tobit and CLAD models appropriate? Value in Health, 13(4), 487–494. CrossRefPubMed
21.
go back to reference Powell, J. L. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25(3), 303–325. CrossRef Powell, J. L. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25(3), 303–325. CrossRef
22.
go back to reference Jolliffe, D., Krushelnytskyy, B., & Semykina, A. (2000, November). Censored least absolute deviations estimator: CLAD. Stata Technical Bulletin, 58, 13–16. Jolliffe, D., Krushelnytskyy, B., & Semykina, A. (2000, November). Censored least absolute deviations estimator: CLAD. Stata Technical Bulletin, 58, 13–16.
23.
go back to reference Longworth, L., & Rowen, D. (2011). NICE DSU technical support document 10: The use of mapping methods to estimate health state utility values. Decision Support Unit, ScHARR, University of Sheffield. Longworth, L., & Rowen, D. (2011). NICE DSU technical support document 10: The use of mapping methods to estimate health state utility values. Decision Support Unit, ScHARR, University of Sheffield.
24.
go back to reference Browne, C., Brazier, J., Carlton, J., Alavi, Y., & Jofre-Bonet, M. (2012). Estimating quality-adjusted life years from patient-reported visual functioning. Eye, 26(10), 1295–1301. CrossRefPubMedPubMedCentral Browne, C., Brazier, J., Carlton, J., Alavi, Y., & Jofre-Bonet, M. (2012). Estimating quality-adjusted life years from patient-reported visual functioning. Eye, 26(10), 1295–1301. CrossRefPubMedPubMedCentral
25.
go back to reference Sengupta, N., Nichol, M. B., Wu, J., & Globe, D. (2004). Mapping the SF-12 to the HUI3 and VAS in a managed care population. Medical Care, 42(9), 927–937. CrossRefPubMed Sengupta, N., Nichol, M. B., Wu, J., & Globe, D. (2004). Mapping the SF-12 to the HUI3 and VAS in a managed care population. Medical Care, 42(9), 927–937. CrossRefPubMed
26.
go back to reference Brazier, J., Yang, Y., Tsuchiya, A., & Rowen, D. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–225. CrossRefPubMed Brazier, J., Yang, Y., Tsuchiya, A., & Rowen, D. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–225. CrossRefPubMed
27.
go back to reference Payakachat, N., Summers, K., Pleil, A., Murawski, M., Thomas, J., Jennings, K., et al. (2009). Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Quality of Life Research, 18(9210257, bqm), 801–813. Payakachat, N., Summers, K., Pleil, A., Murawski, M., Thomas, J., Jennings, K., et al. (2009). Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Quality of Life Research, 18(9210257, bqm), 801–813.
28.
go back to reference Dakin, H., Gray, A., & Murray, D. (2013). Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Quality of Life Research, 22(3), 683–694. CrossRefPubMedPubMedCentral Dakin, H., Gray, A., & Murray, D. (2013). Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Quality of Life Research, 22(3), 683–694. CrossRefPubMedPubMedCentral
29.
go back to reference Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., et al. (2014). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment, 18(34), 1. CrossRefPubMedPubMedCentral Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., et al. (2014). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment, 18(34), 1. CrossRefPubMedPubMedCentral
30.
go back to reference Ara, R., & Brazier, J. E. (2010). Populating an economic model with health state utility values: Moving toward better practice. Value in Health, 13(5), 509–518. CrossRefPubMed Ara, R., & Brazier, J. E. (2010). Populating an economic model with health state utility values: Moving toward better practice. Value in Health, 13(5), 509–518. CrossRefPubMed
31.
go back to reference IVAN Study Team. (2011). IVAN study protocol V7.0: NIHR technology assessment programme. IVAN Study Team. (2011). IVAN study protocol V7.0: NIHR technology assessment programme.
32.
go back to reference Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making, 26(1), 18–29. CrossRefPubMed Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making, 26(1), 18–29. CrossRefPubMed
Metagegevens
Titel
Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L
Auteurs
Padraig Dixon
Helen Dakin
Sarah Wordsworth
Publicatiedatum
01-04-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1145-x